Introduction: Some of the substitutions in these variants have been detected arising independently on multiple genetic backgrounds, such as the spike substitutions N501Y, E484K or the 69-70 deletion, supporting a model of convergent evolution.
Result: Two other closely studied spike substitutions, E484K and L452R, were not notably enriched among vaccine breakthrough cases, and the D253G substitution was modestly depleted.
A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients.
Discussion: There was another sequence sampled from Shiraz in Oct 2020 that contained five specific mutations (D138Y, D614G, E484K, K417T, N501Y) as indicator of the Gamma variant (GR/501Y.V3 (P.1+P.1.x)) and was clustered along with the representative Gamma variant spike sequence in phylogenetic tree.
Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine.
Abstract: Further, we engineer a potent ACE2-blocking nAb to sustain binding to S RBD with the E484K and L452R substitutions found in multiple SARS-CoV-2 variants.
Result: E484K:an escape mutant found in many different variants, including B.1.351 and A.VOI.V2 :did, however, reduce the binding affinity of N-612-017 by 6- to 10-fold (Figures 6A and 6B).
Result: Generation of E484K- and L452R-resistant N-612-017.
Result: Interestingly, both N-612-017-01 and N-612-017-03 subclones not only exhibited restored binding affinity against E484K-expressing RBD variants, but they had 10- to 20-fold enhanced affinity against wild-type RB
Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients.
Method: The beta variant contained the following spike changes: L18F, D80A, D215G, del241-243, K417N, E484K, N501Y, D614G, and A701V.
Mutations in the receptor-binding domain of human SARS CoV-2 spike protein increases its affinity to bind human ACE-2 receptor.
PMID: 35109768
2022
Journal of biomolecular structure & dynamics
Abstract: Here, we use the crystal structure of the RBD in complex with ACE-2 available in the public domain and analyse the 250 ns molecular dynamics (MD) simulations of wild-type and mutants; K417N, K417T, N440K, N501Y, L452R, T478K, E484K and S494P.
Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model.
Discussion: The Beta and Gamma variants are the most resistant to monoclonal antibodies (mAbs) and convalescent plasma from SARS CoV-2-infected individuals, and the resistance profiles correspond to several deletions in the N-terminal domain and the K417N/T, E484K/Q, and N501Y mutations in the RBD of SARS-CoV-2 Spike protein.
Discussion: The E484 position was identified as a dominant residue for escape from neutralizing activity by sera from COVID-19 convalescent patients with the E484K mutation in the SARS-CoV-2 Beta variant as the key factor responsible for the reduced neutralization potency of c
Emergence of a novel SARS-CoV-2 Pango lineage B.1.1.526 in West Bengal, India.
PMID: 34896696
2022
Journal of infection and public health
Abstract: CONCLUSIONS: The D614G, P618H and
Table: E484K
Figure: (C) The sub-branch of the new lineage (B.1.1.526) illustrating 27 strains with additional S: E484K mutation.
Discussion: Interestingly, among 129 SARS-CoV-2 strains that encompass the novel lineage B.1.1.526, 27 strains harbor E484K mutation, which described to have role in immune evasion.
Discussion: Therefore, the novel lineage B.1.1.526 having D614G, P681H, V1230L and E484K mutations in the S glycoprotein is expected to have increased infectivity, high transmissibility, and enhanced immune evasion properties.
Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern.
PMID: 35093484
2022
The Journal of allergy and clinical immunology
Abstract: Interestingly, all 3 vaccines could neutralize all tested variants of concern in addition to WT virus, but in some individuals, only low or no neutralization, especially against Alpha-E484K and the Delta variant, was detected.
Abstract: We also determined the neutralization ability against SARS-CoV-2 WT and B.1.1.7 (Alpha), B1.1.7 E484K (Alpha-E484K), B.1.351 (Beta), and B.1.617.2 (Delta) variants.
SARS_CoV_2 mutation literature information.
PMID: 
2022
ACS infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT